Yongxiang Zhao | Gene Therapy | Best Researcher Award

Prof. Dr Yongxiang Zhao,Guangxi Medical University,China

Prof. Dr. Yongxiang Zhao, Director of the State Key Laboratory of Targeted Oncology, is a renowned expert in tumor diagnosis and treatment. A recipient of the Ho Leung Ho Lee Award 🏆 and a leader in the Yangtze River Scholars Award Program, he pioneered the world’s first gene-edited liver cancer monkey model 🧬 and developed the first intravenous recombinant NDV oncolytic virus 🦠, showing a 90% disease control rate in Phase III trials. With over 160 SCI papers 📄 and 46 invention patents, he has led 30+ major drug development projects, shaping the future of cancer therapy. 🚀

Publication Profile

Scopus

Outstanding Leadership and Recognition

Prof. Dr. Yongxiang Zhao 🎓 is a globally renowned researcher and a visionary leader in the scientific community. As the Director of the State Key Laboratory of Targeted Oncology 🏥, he has spearheaded groundbreaking advancements in cancer research. His outstanding achievements have earned him prestigious honors, including the Ho Leung Ho Lee Award 🏆. Additionally, he leads national innovation programs such as the Yangtze River Scholars Award Program Innovation Team 🌊 and the Ten Thousand Talents Program 🌟. These recognitions underscore his influential role in shaping the future of scientific discovery and fostering innovation on a national and international scale.

Contributions to Oncology

Prof. Dr. Yongxiang Zhao 🎓 has made groundbreaking contributions to oncology, particularly in targeted tumor diagnosis and treatment. He pioneered the development of the world’s first gene-edited liver cancer monkey model 🧬🐒, a revolutionary advancement that has transformed cancer research. This innovative model provides an exceptionally accurate system for studying liver cancer, paving the way for more effective treatment strategies 💊. His work has significantly enhanced our understanding of tumor progression and therapeutic interventions, solidifying his reputation as a leader in oncology 🔬. Through his pioneering research, Dr. Zhao continues to drive innovation and shape the future of cancer treatment.

Breakthrough Innovations in Cancer Treatment

Prof. Dr. Yongxiang Zhao 🎓 has achieved a groundbreaking milestone in cancer treatment with the development of the world’s first intravenous recombinant Newcastle Disease Virus (NDV) oncolytic virus 🦠💉. This revolutionary therapy targets 13 advanced cancers, including liver cancer, offering a promising new approach to oncology. Multi-center clinical trials demonstrated an impressive Disease Control Rate (DCR) of 90% 📊, leading to Phase III clinical trials. This breakthrough has the potential to transform cancer therapy, providing new hope to patients worldwide 🌍. Dr. Zhao’s innovative work continues to push the boundaries of medical science, redefining the future of cancer treatment.

Extensive Research and Intellectual Property

Prof. Dr. Yongxiang Zhao 🎓 is a prolific researcher whose contributions have profoundly impacted oncology and drug development. With over 160 SCI publications 📄, including influential papers in top-tier journals like Cell 🧬, his work has advanced scientific understanding in the field. His innovative mindset is reflected in 46 invention patents 🏅, highlighting his role as a pioneer in medical research. Leading over 30 major national drug development projects 💊, Dr. Zhao has played a crucial role in translating groundbreaking discoveries into real-world medical applications, shaping the future of cancer treatment and improving patient outcomes globally 🌍.

Research Focus

Dr. Yongxiang Zhao’s research primarily focuses on nanomedicine, drug delivery systems, and cancer therapeutics. His work spans polymeric nanoparticles 🧪, exosomal RNA therapies 🧬, and aptamer-based antiviral strategies 🦠, particularly targeting multidrug-resistant bacterial infections and cancer treatment 🎗️. He also explores biocompatible microspheres for tissue repair 🏥 and oncology-focused biomaterials. His research integrates biomedical engineering 🏗️, molecular biology 🧫, and clinical applications. Dr. Zhao’s contributions extend to tumor microenvironment studies, cancer-associated fibroblasts 💊, and immunotherapeutic bacteria 🦠 for precision medicine, making significant strides in advanced therapeutics and biomaterials development.

Publication Top Notes

Moxifloxacin-Loaded Polymeric Nanoparticles for Overcoming Multidrug Resistance in Chronic Pulmonary Infections Caused by Pseudomonas aeruginosa

The function of albumin and its application in tumor therapy

Aptamers targeting SARS-CoV-2 nucleocapsid protein exhibit potential anti pan-coronavirus activity

Heterogeneity and interplay: the multifaceted role of cancer-associated fibroblasts in the tumor and therapeutic strategies

Exosomal lncRNA ROR1-AS1 from cancer-associated fibroblasts inhibits ferroptosis of lung cancer cells through the IGF2BP1/SLC7A11 signal axis

Correction to: Engineering a precise adenine base editor with minimal bystander editing (Nature Chemical Biology, (2023), 19, 1, (101-110), 10.1038/s41589-022-01163-8)

Polymer Microspheres and Their Application in Cancer Diagnosis and Treatment

Microalgae-loaded biocompatible alginate microspheres for tissue repair

Landscape of global urban environmental resistome and its association with local socioeconomic and medical status

Oncolytic mineralized bacteria as potent locally administered immunotherapeutics